Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T63267 |
P-gp/BCRP-IN-1
|
||
P-gp/BCRP-IN-1 (compound 19) 是一种潜在的、相对安全的、口服有效的外排转运蛋白(P-gp 和 BCRP) 抑制剂。P-gp/BCRP-IN-1 通过抑制 P-gp 和BCRP 的外排功能产生耐药性逆转,P-gp/BCRP-IN-1可克服紫杉醇的耐药性,提高紫杉醇的口服生物利用度。 | |||
T72473 |
NOD1/2 antagonist-1
|
||
NOD1/2 antagonist-1 是一种有效的NOD1/2双拮抗剂,其IC50值分别为 1.13 (NOD1) 和 0.77 μM (NOD2)。NOD1/2 antagonist-1 有可接受的 T1/2(67.6 min)。NOD1/2 antagonist-1 可提高紫杉醇 (PTX) 的抗肿瘤作用。 | |||
T69162 |
Ki23057
|
||
Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism betwee... |